key: cord-0947323-j12y6k6o authors: Morsy, Sara title: NCAM protein and SARS-COV-2 surface proteins: in-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré Syndrome date: 2020-10-08 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.110342 sha: 83a33f3458725ac3f4883a44b8fa939419a627a3 doc_id: 947323 cord_uid: j12y6k6o This study aimed at identifying human neural proteins that can be attacked by cross-reacting SARS-COV-2 antibodies causing Guillain-Barré Syndrome. These markers can be used for the diagnosis of Guillain-Barré Syndrome (GBS). To achieve this goal, proteins implicated in the development of GBS were retrieved from literature. These human proteins were compared to SARS-COV-2 surface proteins to identify homologous sequences using Blastp. Then, MHC-I and MHC-II epitopes were determined in the homologous sequences and used for further analysis. Similar human and SARS-COV-2 epitopes were docked to the corresponding MHC molecule to compare the binding pattern of human and SARS-COV-2 proteins to the MHC molecule. Neural cell adhesion molecule is the only neural protein that showed homologous sequence to SARS-COV-2 envelope protein. The homologous sequence was part of HLA-A68 and HLA-DQA/HLA-DQB epitopes had a similar binding pattern to SARS-COV-2 envelope protein. Based on these results, the study suggests that NCAM may play a significant role in the immunopathogenesis of GBS. NCAM antibodies can be used as a marker for Guillain-Barré Syndrome. However, more experimental studies are needed to prove these results Currently, few studies reported that severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection was associated with the occurrence of Guillain-Barré syndrome that is considered the most frequent post-infection acute paralytic neuropathy (1) (2) (3) (4) . Guillain-Barré syndrome did not have the best prognosis since only 20% survive with disabilities and a 5% mortality rate (5) . Moreover, it is estimated that 20% to 30% of cases had a respiratory failure (6) . Usually, Guillain-Barré syndrome is preceded by infections that cause an autoimmune response against peripheral nerves (5, 6) . It is not the first time that the SARS-COV-2 infection caused neurologic manifestations. In a cohort of 214 hospitalized patients, it was estimated that neurologic symptoms appeared in 36% of the patients (7) . Guillain-Barré syndrome is reported in different coronaviruses' infection, however, the exact mechanism is not well understood (8, 9) . In Northern Italy, five patients were diagnosed as COVID-19 developed symptoms of Guillain-Barré syndrome within 5 -10 days after infection. Three patients were tested negative for gangliosides antibodies. All cases had poor to moderate outcomes with two of them remained in intensive care units (2) . 61 years old Chinese female developed Guillain-Barré syndrome after seven days of COVID-19 diagnosis. The patient had a full recovery after 30 days of infection, however, the patient was not tested for any antibodies (3) . Another case in the United States developed Guillain-Barré syndrome and tested positive for SARS-COV-2. The patients had not recovered completely but patients had weakness in the lower extremities (4) . Another case in Iran developed symptoms and signs, however, no antibody tests were done for the patient (1). The mechanism of the induction of Guillain-Barré syndrome is still not understood in the SARS-COV-2 infection as many studies did not perform diagnostic tests to identify the neural antibodies. Understanding the mechanism would provide an insight into the disease immunopathogenesis. Hence, in this study, through the computational approach, the possibility of similar epitopes between SARS-COV-2 surface proteins and neuronal proteins was investigated. The epitope mimicry between surface proteins of SARS-COV-2 and human neural proteins is responsible for the autoimmune mechanism underlying Guillain-Barré Syndrome. In this study, the NCAM protein was identified as the target proteins responsible for the development of Guillain-barré Syndrome in these patients. Besides, two HLA molecules either HLA-A*68 and HLA-DQA1/HLA-DQB1 could bind the homologous sequence in both humans and SARS-COV-2. These specific HLA distributions would explain the occurrence of Guillain-Barré Syndrome in a specific population and not in all COVID-19 patients. NCAM is not only expressed in neural tissues but also expressed in cardiac and skeletal muscles (10) . In different myopathies, decreased NCAM protein in muscles is considered important pathogenesis in these diseases as it was linked to denervation of the muscles (11) . This is considered crucial for more understanding of the respiratory distress in COVID-19 patients as respiratory muscle weakness can be considered one of the causes of respiratory distress (12, 13) . That is why this hypothesis is important for more understanding of the immunopathogenesis of COVID-19 The hypothesis was evaluated using a bioinformatics approach through molecular mimicry analysis to identify possible neural proteins that can be attacked by cross-reacting immune cells. Besides, molecular docking was performed to confirm the strength of binding of cross-reacting immune cells to the human neural protein. The amino acid sequence of the membrane glycoproteins, envelope proteins, and surface glycoprotein of SARS-COV-2 reference proteins were used as query proteins (RefSeq ID: NC_045512) from the NCBI virus database (14) . (15) (16) (17) (18) (19) (20) . The amino acid sequence of each protein was retrieved from the Uniprot database (21) . The search was refined to reviewed proteins and expressed in Homo Sapiens. BLASTp program (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to find the homologous sequence between the human proteins implicated in Guillain-Barré syndrome and structural proteins of SARS-COV-2 (22) . Only homologous peptides of five amino acids or more were selected for epitope prediction and docking (20) . The detected homologous sequences were then used in the IEDB database (http://www.iedb.org) to find immune epitopes in both human and SARS-COV-2 homologous sequences for MHC-I and MHC-II molecules (23) . For the epitope to be selected for further analysis, the epitope should contain the homologous sequence as well as has the same binding HLA molecule for both human and SARS-COV-2 proteins. The IEDB recommended models and parameters were used. For HLA selection, the HLA allele reference set for both MHC-I and MHC-II was selected (23) . To confirm the results, the homologous epitopes recovered from the IEDB database were docked to corresponding MHC molecules using GalaxyPepDock (http://galaxy.seoklab.org/) server (24) . The docked models were analyzed using UCSF Chimera 1.14 (25) and LigPLOT+ (26) for similarity in hydrogen bonds. The crystal structure of HLA-A*68 and HLA-DQ1 were obtained from the Protein Data Bank database (PDB ID: 4I48, and 3PL6). These crystal structures were inspected and modified to remove any bound ligands and make the groove available for the docking with SARS-COV-2 and human proteins using UCSF-Chimera 1.14 (25) . The only human neural protein that had a homologous sequence to surface SARS-COV-2 proteins was the neuronal cell adhesion molecule (NCAM) which was homologous to envelop proteins. The envelope proteins are 85% identical to NCAM. The homologous sequence is TGTLIIN for NCAM corresponding to TGTLIVN for envelope proteins. Based on the present study results, the cause of Guillain-Barré syndrome in SARS-COV-2 is epitope mimicry between envelope proteins and NCAM. In addition, two HLA molecules were involved either HLA-A*68 and HLA-DQA1/HLA-DQB1. The Neural cell adhesion molecule is a neuronal surface adhesion protein that is widely expressed in neural cells. In addition, NCAM was expressed in myelinating Schwan cells, cardiac and skeletal muscles (27) . It is important for cell function, adhesion, and differentiation. It has many isoforms depending on mRNA splicing (10) . Another study found that it was overexpressed in cases of neuronal regeneration and remyelination (27) . It was implicated in other diseases as Alzheimer's disease, multiple sclerosis, and neuroblastoma (28) (29) (30) (31) . The NCAM is expressed in nodal tissues like nodes of Ranvier. A study found that nodal and paranodal membrane injury is one of the main pathologies in Guillain-Barré syndrome resulting in an axonal injury that clinically will lead to paralysis (32) . It also assessed antibodies against NCAM in Guillain-Barré syndrome patients found that 29 out of 150 had positive antibodies (32) . Peripheral neuropathy was also evident in leprosy which is caused by Mycobacterium leprae (M. Leprae) that alter the expression of NCAM (33) . Furthermore, MHC-II attack Schwann cells infected with M. Leprae implying similar immunopathogenesis as suggested in the current study (33) . Another study found that sera from patients diagnosed with demyelinating disorders including Guillain-Barré syndrome reacted against NCAM, however, it was nonsignificant even though it was detected in around half of the patients (29). This is not the first time that viral infection causes Guillain-Barré syndrome. It is well-evident in the Zika infection and herpes virus infection (34, 35) . In addition, neuropathies were also evident in SARS and MERS infection (8, 36, 37) . There is also an evident association between HLA antigens and Guillain-Barré syndrome (38, 39) . There was a significant association between HLA-DQ in Guillain-Barré syndrome caused by campylobacter jejune (38, 40) . Another study found that HLA-DQ1 was associated with severe forms of Guillain-Barré syndrome which is consistent with the current study (41) . Blum et al. discovered that HLA is also an important factor for the development of Guillain-Barré syndrome through the activation of Natural killer cells which had a crucial role in the development of Guillain-Barré syndrome (42) . Guillain Barre syndrome associated with COVID-19 infection: A case report Guillain-Barré Syndrome Associated with SARS-CoV-2 Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Guillain-Barré Syndrome associated with SARS-CoV-2 infection Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Neurological Complications during Treatment of Middle East Respiratory Syndrome Nervous system involvement after infection with COVID-19 and other coronaviruses Structure and Function of the Neural Cell Adhesion Molecule NCAM NCAM, vimentin and neonatal myosin heavy chain expression in human muscle diseases Muscle Weakness and 5-Year Survival in Acute Respiratory Distress Syndrome Survivors Respiratory Muscle Fatigue: A Cause of Respiratory Failure? Virus Variation Resource -improved response to emergent viral outbreaks Nodal proteins are target antigens in Guillain-Barre syndrome Paranodal and other autoantibodies in chronic inflammatory neuropathies Moesin is a possible target molecule for cytomegalovirusrelated Guillain-Barre syndrome Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barre syndrome Zika virus and autoimmunity: From microcephaly to Guillain-Barré syndrome, and beyond UniProt: a worldwide hub of protein knowledge Protein database searches using compositionally adjusted substitution matrices The Immune Epitope Database (IEDB): 2018 update GalaxyPepDock: a protein-peptide docking tool based on interaction similarity and energy optimization UCSF Chimera--a visualization system for exploratory research and analysis LigPlot+: multiple ligand-protein interaction diagrams for drug discovery Neurobiology of Brain Disorders Plasma levels of soluble NCAM in multiple sclerosis Reactivity with neural cell adhesion molecules in sera from patients with demyelinating diseases Aβ-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease Expression of the neural cell adhesion molecule and polysialic acid in human neuroblastoma cell lines Nodal proteins are target antigens in Guillain-Barré syndrome The biology of nerve injury in leprosy Guillain-Barré Syndrome After Zika Virus Infection in Brazil Increased Risk of Guillain-Barré Syndrome following Recent Herpes Zoster: A Population-Based Study across Taiwan Peripheral nerve disease in SARS:: report of a case Neuromusculoskeletal disorders following SARS: a case series HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis Human leukocyte antigen-DQB1 polymorphisms and haplotype patterns in Guillain-Barré syndrome Higher frequencies of HLA DQB1*05:01 and antiglycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests